Is ITP a thrombophilic disorder?
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Immune thrombocytopenia (ITP) represents the epitome of acquired bleeding diseases for the hematologist. Stemming from the interest for the safety of thrombopoietin‐receptor agonists (TPO‐ra) romiplostim and eltrombopag, recent data have investigated if thrombotic risk is also increased in this disorder. In patients not treated with TPO‐ra, a slightly higher risk of venous thrombosis (VTE) is consistently found in ITP, but not to a rate demanding special attention in the generality of cases. No significant increase of arterial thrombosis (AT) is apparent. However, age, splenectomy, and personal risk factors may put some ITP patient to a particularly higher risk of venous and arterial thrombosis (three to four times higher than the average subject). Patients exposed to TPO‐ra present indirect evidence of a much higher risk of both AT and VTE. Unfortunately, no matched control population is available and the prospective and registrative nature of these studies may have emphasized the incidence of thrombosis, which was recorded as adverse event. The clinician should be able to individualize the best treatment for the patient, taking also into account the thrombotic risk, limiting active treatment of ITP to those patients really at risk of bleeding. Am. J. Hematol. 91:39–45, 2016. © 2015 Wiley Periodicals, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MIYAKIS, S., LOCKSHIN, M. D., ATSUMI, T., BRANCH, D. W., BREY, R. L., CERVERA, R., DERKSEN, R. H. W. M., DE GROOT, P. G., KOIKE, T., MERONI, P. L., et al. (2006) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2006.01753.x · Cited by 7,203 · cited 1×
“A high titer of APA characterizes a distinct clinical entity called antiphospholipid syndrome (APS), which could be associated with thromboctytopenia in up to 30%–45% of patients, but requires for its diagnosis the obligatory occurrence of clinical events such as venous or arterial thrombosis, or some complications of…”
BackgroundRodeghiero, F., Stasi, R., Gernsheimer, T., Michel, M., Provan, D., Arnold, D. M., Bussel, J. B., Cines, D. B., Chong, B. H., Cooper, N., et al. (2009) · Blood · doi:10.1182/blood-2008-07-162503 · Cited by 2,690 · cited 2×
“When a patient with ITP, consistently positive for APA antibodies—a situation which does not in itself exclude a diagnosis of primary ITP [2]—develops a thrombotic event during the course of the disease, thus meeting the Sapporo criteria, it remains uncertain if we are dealing with a true APS.”
BackgroundSelf-citationProvan, D., Stasi, R., Newland, A. C., Blanchette, V. S., Bolton-Maggs, P., Bussel, J. B., Chong, B. H., Cines, D. B., Gernsheimer, T. B., Godeau, B., et al. (2010) · Blood · doi:10.1182/blood-2009-06-225565 · Cited by 2,271
Self-citationNeunert, C., Lim, W., Crowther, M., Cohen, A., Solberg, L., & Crowther, M. A. (2011) · Blood · doi:10.1182/blood-2010-08-302984 · Cited by 1,856
Incidence and mortality of venous thrombosis: a population‐based study
NÆSS, I. A., CHRISTIANSEN, S. C., ROMUNDSTAD, P., CANNEGIETER, S. C., ROSENDAAL, F. R., & HAMMERSTRØM, J. (2007) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2007.02450.x · Cited by 1,413
Incidence of Venous Thromboembolism: A Community-based Study in Western France
Oger, E., & the EPI-GETBO Study Group (2000) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1613887 · Cited by 711
Kojouri, K., Vesely, S. K., Terrell, D. R., & George, J. N. (2004) · Blood · doi:10.1182/blood-2004-03-1168 · Cited by 653 · cited 1×
“successful rate in about two-third of cases [23] and still remains the”
BackgroundSaleh, M. N., Bussel, J. B., Cheng, G., Meyer, O., Bailey, C. K., Arning, M., & Brainsky, A. (2013) · Blood · doi:10.1182/blood-2012-04-425512 · Cited by 336
Vascular complications after splenectomy for hematologic disorders
Crary, S. E., & Buchanan, G. R. (2009) · Blood · doi:10.1182/blood-2009-04-210112 · Cited by 323 · cited 1×
“Comprehensive reviews on vascular complications after splenectomy for hematological disorders in general [25], or limited to benign ones only [6] have been published.”
BackgroundKuter, D. J., Bussel, J. B., Newland, A., Baker, R. I., Lyons, R. M., Wasser, J., Viallard, J., Macik, G., Rummel, M., Nie, K., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12260 · Cited by 275
Nugent, D., McMillan, R., Nichol, J. L., & Slichter, S. J. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07717.x · Cited by 270 · cited 1×
“Its pathogenesis has been clarified by demonstrating its autoimmune origin, with autoantibody against platelet membrane Gp IIb/IIIa and Gp Ib causing platelet destruction [3] and insufficient compensatory platelet production [4], thus resulting in decreased platelet count.”
BackgroundRodeghiero, F., Michel, M., Gernsheimer, T., Ruggeri, M., Blanchette, V., Bussel, J. B., Cines, D. B., Cooper, N., Godeau, B., Greinacher, A., et al. (2013) · Blood · doi:10.1182/blood-2012-07-442392 · Cited by 246
Self-citationSarpatwari, A., Bennett, D., Logie, J. W., Shukla, A., Beach, K. J., Newland, A. C., Sanderson, S., & Provan, D. (2010) · Haematologica · doi:10.3324/haematol.2009.018390 · Cited by 241 · cited 3×
“In summary, all population-based studies using either patients without ITP registered in clinical practice [12] or matched subjects from general population [13,15,16] show evidence that the risk for VTE is higher (around two times) in chronic ITP compared with controls.”
BackgroundDiz-Küçükkaya, R., Hacıhanefioǧlu, A., Yenerel, M., Turgut, M., Keskin, H., Nalçacı, M., & l˙nanç, M. (2001) · Blood · doi:10.1182/blood.v98.6.1760 · Cited by 225
Boyle, S., White, R. H., Brunson, A., & Wun, T. (2013) · Blood · doi:10.1182/blood-2012-12-467068 · Cited by 213 · cited 2×
“There is a clear increase (three- to four-fold) of lifelong risk of VTE and AT in splenectomized patients [20,27] which was also evident in some retrospective single cohort studies [5,26].”
BackgroundBasser, R. L., Rasko, J. E. J., Clarke, K., Cebon, J. S., Green, M. D., Grigg, A., Zalcberg, J. R., Cohen, B., O’Byrne, J., Menchaca, D., et al. (1997) · PubMed · doi:10.1182/blood.v89.9.3118 · Cited by 196
Aledort, L. M., Hayward, C. P. M., Chen, M., Nichol, J. L., & Bussel, J. (2004) · American Journal of Hematology · doi:10.1002/ajh.20104 · Cited by 191 · cited 2×
“raised great interest and paved the way to further analyses of this issue [11].”
BackgroundStasi, R., Stipa, E., Masi, M., Oliva, F., Sciarra, A., Perrotti, A., Olivieri, M., Zaccari, G., Gandolfo, G., & Galli, M. (1994) · Blood · doi:10.1182/blood.v84.12.4203.bloodjournal84124203 · Cited by 162
Severinsen, M. T., Engebjerg, M. C., Farkas, D. K., Jensen, A. Ø., Nørgaard, M., Zhao, S. Z., & Sørensen, H. T. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08418.x · Cited by 156 · cited 2×
“In summary, all population-based studies using either patients without ITP registered in clinical practice [12] or matched subjects from general population [13,15,16] show evidence that the risk for VTE is higher (around two times) in chronic ITP compared with controls.”
BackgroundRodeghiero, F., & Ruggeri, M. (2012) · British Journal of Haematology · doi:10.1111/j.1365-2141.2012.09146.x · Cited by 132 · cited 2×
“Comprehensive reviews on vascular complications after splenectomy for hematological disorders in general [25], or limited to benign ones only [6] have been published.”
BackgroundResultSelf-citationKhellaf, M., Michel, M., Quittet, P., Viallard, J., Alexis, M., Roudot‐Thoraval, F., Chèze, S., Durand, J. M., Lefrère, F., Galicier, L., et al. (2011) · Blood · doi:10.1182/blood-2011-03-340166 · Cited by 123
Psaila, B., Bussel, J. B., Linden, M. D., Babula, B., Li, Y., Barnard, M. R., Tate, C. M., Mathur, K., Frelinger, A. L., & Michelson, A. D. (2012) · Blood · doi:10.1182/blood-2011-11-393900 · Cited by 119 · cited 1×
“In vitro experiments, where platelets were exposed to these agents, and limited laboratory investigations carried out in patients taking TPO-ra, did not show consistent platelet function modifications directly linked to hyperactivity [31,32].”
BackgroundSchiffer, C. A., Miller, K. B., Larson, R. A., Amrein, P. C., Antin, J. H., Zani, V. J., & Stone, R. M. (2000) · Blood · doi:10.1182/blood.v95.8.2530 · Cited by 118
Nørgaard, M., Severinsen, M. T., Mægbæk, M. L., Jensen, A. Ø., Cha, S., & Sørensen, H. T. (2012) · British Journal of Haematology · doi:10.1111/j.1365-2141.2012.09231.x · Cited by 66
Haselböck, J., Kaider, A., Pabinger, I., & Panzer, S. (2013) · Thrombosis and Haemostasis · doi:10.1160/th12-07-0522 · Cited by 33 · cited 1×
“In vitro experiments, where platelets were exposed to these agents, and limited laboratory investigations carried out in patients taking TPO-ra, did not show consistent platelet function modifications directly linked to hyperactivity [31,32].”
Background
Cited by
Cooper, N., & Ghanima, W. (2019) · New England Journal of Medicine · doi:10.1056/nejmcp1810479 · Cited by 503
Thrombopoietin receptor agonists: ten years later
Ghanima, W., Cooper, N., Rodeghiero, F., Godeau, B., & Bussel, J. B. (2019) · Haematologica · doi:10.3324/haematol.2018.212845 · Cited by 416
Self-citation
Metadata
- Authors
- Rodeghiero, F.
- Venue
- American Journal of Hematology
- Publisher
- Wiley
- Published
- 2015-11-26
- Volume
- 91
- Issue
- 1
- Pages
- 39-45
- ISSN
- 0361-8609 (ISSN-L)
- 1096-8652
- OpenAlex
- W2141190443
- Cited by
- 159
- References
- 26
- FWCI
- 7.24
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.